BR112020002519A2 - composto de piridina substituído por azol - Google Patents

composto de piridina substituído por azol Download PDF

Info

Publication number
BR112020002519A2
BR112020002519A2 BR112020002519-4A BR112020002519A BR112020002519A2 BR 112020002519 A2 BR112020002519 A2 BR 112020002519A2 BR 112020002519 A BR112020002519 A BR 112020002519A BR 112020002519 A2 BR112020002519 A2 BR 112020002519A2
Authority
BR
Brazil
Prior art keywords
substituted
carboxy
formula
replaced
ring
Prior art date
Application number
BR112020002519-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Hiroaki Tanaka
Madoka Kawamura
Makoto Hamada
Yohei Kobashi
Yuji Ito
Kazuaki Suzuki
Ayako Bohno
Kosuke Funayama
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of BR112020002519A2 publication Critical patent/BR112020002519A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112020002519-4A 2017-08-10 2018-08-10 composto de piridina substituído por azol BR112020002519A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017171584 2017-08-10
JP2017-171584 2017-08-10
PCT/JP2018/030456 WO2019031618A1 (fr) 2017-08-10 2018-08-10 Composé de pyridine substitué par un azole

Publications (1)

Publication Number Publication Date
BR112020002519A2 true BR112020002519A2 (pt) 2020-08-04

Family

ID=65271252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020002519-4A BR112020002519A2 (pt) 2017-08-10 2018-08-10 composto de piridina substituído por azol

Country Status (15)

Country Link
US (1) US11365192B2 (fr)
EP (1) EP3666766A4 (fr)
JP (1) JP7052798B2 (fr)
KR (1) KR20200038457A (fr)
CN (1) CN110914254A (fr)
AU (1) AU2018312680A1 (fr)
BR (1) BR112020002519A2 (fr)
CA (1) CA3072420A1 (fr)
IL (1) IL272482A (fr)
MX (1) MX2020001615A (fr)
PH (1) PH12020500292A1 (fr)
RU (1) RU2020109674A (fr)
SG (1) SG11202000976TA (fr)
TW (1) TW201920134A (fr)
WO (1) WO2019031618A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202045494A (zh) * 2019-02-08 2020-12-16 日商大正製藥股份有限公司 經雜芳基取代的吡啶化合物
CN115073308A (zh) * 2021-03-15 2022-09-20 苏州信礼发医药技术有限公司 1-氨甲基-1-环丙醇的合成方法
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN115557898A (zh) * 2021-07-01 2023-01-03 诸葛国琴 一种咪唑类化合物、其中间体及应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785148B1 (ko) 1999-11-01 2007-12-11 다이쇼 세이야꾸 가부시끼가이샤 20-hete 생산 효소 저해제
EP1294685A1 (fr) 2000-06-29 2003-03-26 Abbott Laboratories Derives de sulfure d'aryle phenycyclopropyle et leur utilisation en tant que composes anti-inflammatoires inhibant l'adhesion cellulaire et agents immunosuppresseurs
JPWO2003022821A1 (ja) 2001-09-06 2004-12-24 大正製薬株式会社 20−hete産生酵素阻害作用を有するヘテロ環誘導体
JP2004262890A (ja) * 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd 20−hete産生阻害作用を有するアゾール誘導体
US20060189673A1 (en) 2003-04-14 2006-08-24 Nippon Soda Co., Ltd. Phenylazole compound, production process therefor and antioxidant
EP1650206A4 (fr) 2003-08-01 2006-12-20 Nippon Soda Co Composes de phenylazole, leur procede de production et antioxydants
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
CN105492432B (zh) * 2013-07-31 2019-06-14 住友化学株式会社 四唑啉酮化合物及其用途
JP6351043B2 (ja) 2015-08-04 2018-07-04 株式会社ユニバーサルエンターテインメント 遊技機
US20210040062A1 (en) * 2016-02-15 2021-02-11 Taisho Pharmaceutical Co., Ltd. Azole-substituted pyridine compound

Also Published As

Publication number Publication date
EP3666766A4 (fr) 2021-03-24
CN110914254A (zh) 2020-03-24
PH12020500292A1 (en) 2021-01-25
RU2020109674A (ru) 2021-09-13
CA3072420A1 (fr) 2019-02-14
US20210122741A1 (en) 2021-04-29
MX2020001615A (es) 2020-07-13
IL272482A (en) 2020-03-31
EP3666766A1 (fr) 2020-06-17
WO2019031618A1 (fr) 2019-02-14
AU2018312680A1 (en) 2020-03-19
SG11202000976TA (en) 2020-03-30
WO2019031618A8 (fr) 2019-04-11
JP7052798B2 (ja) 2022-04-12
KR20200038457A (ko) 2020-04-13
JPWO2019031618A1 (ja) 2020-07-30
TW201920134A (zh) 2019-06-01
US11365192B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
BR112020002519A2 (pt) composto de piridina substituído por azol
CA3029202C (fr) Acides carbamoyloxymethyl triazole cyclohexyliques en tant qu&#39;antagonistes de lpa
JP6994496B2 (ja) 芳香族アセチレンまたは芳香族エチレン系化合物、その中間体、製造方法、薬物組成物および使用
RU2692485C2 (ru) Противофиброзные пиридиноны
ES2738148T3 (es) Derivado de ácido hidroxámico
ES2383239T3 (es) Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
BR112020025642A2 (pt) compostos heterocíclicos como inibidores da monoacilglicerol lipase
SK282338B6 (sk) N-Heteroarylpyridínsulfónamidové deriváty, spôsob prípravy, medziprodukty a použitie týchto derivátov ako antagonistov endotelínu
NZ552086A (en) Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
CN103958480A (zh) 咪唑啉类衍生物、其制备方法及其在医药上的应用
AU2020323429A1 (en) Urea compound for antagonizing LPA1 receptor
JP6526275B2 (ja) Ship1モジュレーターおよびそれに関連する方法
JP2023539690A (ja) 複素環式化合物
BR112021009435A2 (pt) derivados de oxopiridina substituída
EP3371167A1 (fr) Pyrazoles d&#39;arylcyclohéxyle utilisés en tant que régulateurs de nrf2
CA3035999A1 (fr) Derives heterocycliques de benzene fusionne et composition pharmaceutique renfermant lesdits derives
CA2901766A1 (fr) N-(2-cyano-heterocyclyl)pyrazolo-pyridones en tant qu&#39;inhibiteurs de la janus kinase
CA3199568A1 (fr) Inhibiteur a petites molecules de la cathepsine c et son utilisation medicinale
CA3115472A1 (fr) Composes et compositions destines au traitement d&#39;etats pathologiques associes a une activite du recepteur de l&#39;apj
TW200950781A (en) Glucocorticoid receptor agonist consisting of derivatives of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline with substituted oxy group
RU2670982C2 (ru) ПРОИЗВОДНЫЕ α-ЗАМЕЩЕННОГО ГЛИЦИНАМИДА
TW202233575A (zh) 用於治療與lpa受體活性相關的病狀的化合物及組合物
JP6006609B2 (ja) 新規なヒドロキサム酸誘導体を含有する医薬
EP1147101B1 (fr) Composes d&#39;hydroxamate inverse utilises comme inhibiteurs de metalloproteases matricielles
JP2020128368A (ja) アゾールで置換されたピリジン化合物を有効成分として含有する医薬

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]